İnternet sitemizde çerez (cookie) kullanılmaktadır. Çerezler (cookie) hakkında detaylı bilgi için Çerez Politikası'nı inceleyiniz. Devam etmeniz halinde çerez (cookie) kullanımına izin verdiğinizi kabul edeceğiz. Çerez ayarlarınızı değiştirmeniz halinde internet sitesinin birtakım özelliklerini kullanamayabileceğinizi belirtmek isteriz.

Lenfoma hücrelerinin daha fazla öldürülmesini sağlayan hipertermi ve bortezomib kombinasyonu

Lenfoma hücrelerinin daha fazla öldürülmesini sağlayan hipertermi ve bortezomib kombinasyonu

Kategori   Hipertermi   Lenfoma   | 12/8/2016

Int J Hyperthermia. 2009 Jun;25(4):262-72. doi: 10.1080/02656730902835664.
Milani V1, Lorenz M, Weinkauf M, Rieken M, Pastore A, Dreyling M, Issels R.
Author information
1Department of Medical Oncology, University Medical Center Grosshadern, 81377 Munich, Germany. valeria.milani@med.uni-muenchen.de
Abstract
The proteasome inhibitor bortezomib exhibits antitumor activity in many malignancies including mantle cell lymphoma (MCL). Unfortunately, many patients fail to respond to treatment or become refractory. Hyperthermia is an effective chemosensitizer that in combination with some chemotherapeutic agents has shown clinical activity in phase II and III studies. The aim of this study was to use MCL cell lines to investigate the potential benefit of combining clinically relevant doses of bortezomib with two different thermal doses (41.8 degrees C/120 min and 44 degrees C/30 min) that mimic the heterogeneity of the temperature distributions achieved within tumors during hyperthermia. Treated tumor cells were assessed for proliferation using the WST-1 assay and for apoptosis by annexin V staining, while heat shock protein (HSP) levels were determined following western blot analysis. Our results demonstrated that MCL cell lines that are sensitive to bortezomib are also thermosensitive and have low basal expression of hsp27, whereas the bortezomib-resistant MCL cell line strongly expresses hsp27 and is thermoresistant. Interestingly, pre-treatment of MCL cell lines with heat at the two different thermal doses, and the transient elevation of hsp27 and hsp70, do not impair their primary sensitivity to bortezomib. Finally, we show that the concurrent treatment of heat and bortezomib results in additive killing in MCL cell lines.In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation.
 
 

Lenfoma hücrelerinin daha fazla öldürülmesini sağlayan hipertermi ve bortezomib kombinasyonu

Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.

Int J Hyperthermia. 2009 Jun;25(4):262-72. doi: 10.1080/02656730902835664.

Milani V1, Lorenz M, Weinkauf M, Rieken M, Pastore A, Dreyling M, Issels R.

Author information

• 1 Department of Medical Oncology, University Medical Center Grosshadern, 81377 Munich, Germany. valeria.milani@med.uni-muenchen.de

Abstract

The proteasome inhibitor bortezomib exhibits antitumor activity in many malignancies including mantle cell lymphoma (MCL). Unfortunately, many patients fail to respond to treatment or become refractory. Hyperthermia is an effective chemosensitizer that in combination with some chemotherapeutic agents has shown clinical activity in phase II and III studies. The aim of this study was to use MCL cell lines to investigate the potential benefit of combining clinically relevant doses of bortezomib with two different thermal doses (41.8 degrees C/120 min and 44 degrees C/30 min) that mimic the heterogeneity of the temperature distributions achieved within tumors during hyperthermia. Treated tumor cells were assessed for proliferation using the WST-1 assay and for apoptosis by annexin V staining, while heat shock protein (HSP) levels were determined following western blot analysis. Our results demonstrated that MCL cell lines that are sensitive to bortezomib are also thermosensitive and have low basal expression of hsp27, whereas the bortezomib-resistant MCL cell line strongly expresses hsp27 and is thermoresistant. Interestingly, pre-treatment of MCL cell lines with heat at the two different thermal doses, and the transient elevation of hsp27 and hsp70, do not impair their primary sensitivity to bortezomib. Finally, we show that the concurrent treatment of heat and bortezomib results in additive killing in MCL cell lines.In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation.